Bio-Works Technologies AB (publ) (BIOWKS.ST)
SEK 1.08
(0.47%)
SEK 1.08
(0.47%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -54.8 Million SEK | -24.0% |
| 2022 | -46.09 Million SEK | -414.22% |
| 2021 | -10.46 Million SEK | 80.92% |
| 2020 | -45.04 Million SEK | -11.79% |
| 2019 | -40.76 Million SEK | -29.91% |
| 2018 | -31.01 Million SEK | -45.39% |
| 2017 | -21.37 Million SEK | -45.31% |
| 2016 | -15.44 Million SEK | -28.63% |
| 2015 | -11.41 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q2 | -29 Million SEK | -94.1% |
| 2023 Q3 | -13.5 Million SEK | 53.45% |
| 2023 Q4 | -13.5 Million SEK | 0.0% |
| 2023 FY | - SEK | -24.0% |
| 2023 Q1 | -14.94 Million SEK | 33.58% |
| 2022 Q4 | -22.49 Million SEK | -98.19% |
| 2022 Q2 | -23.6 Million SEK | -96.95% |
| 2022 Q1 | -11.98 Million SEK | 44.4% |
| 2022 FY | - SEK | -414.22% |
| 2022 Q3 | -11.35 Million SEK | 51.9% |
| 2021 Q2 | -22.39 Million SEK | -566.48% |
| 2021 FY | - SEK | 80.92% |
| 2021 Q1 | 4.8 Million SEK | 139.7% |
| 2021 Q4 | -21.55 Million SEK | -114.79% |
| 2021 Q3 | -10.03 Million SEK | 55.19% |
| 2020 Q3 | -12.09 Million SEK | -25.51% |
| 2020 Q2 | -9.63 Million SEK | 13.53% |
| 2020 Q1 | -11.14 Million SEK | 42.63% |
| 2020 FY | - SEK | -11.79% |
| 2020 Q4 | -12.09 Million SEK | 0.0% |
| 2019 Q2 | -11.01 Million SEK | -11.79% |
| 2019 Q1 | -9.85 Million SEK | 38.39% |
| 2019 FY | - SEK | -29.91% |
| 2019 Q4 | -19.42 Million SEK | -78.85% |
| 2019 Q3 | -10.85 Million SEK | 1.45% |
| 2018 Q2 | -8.26 Million SEK | -22.27% |
| 2018 FY | - SEK | -45.39% |
| 2018 Q4 | -15.99 Million SEK | -118.31% |
| 2018 Q3 | -7.32 Million SEK | 11.32% |
| 2018 Q1 | -6.75 Million SEK | 22.21% |
| 2017 Q3 | -3.62 Million SEK | 25.91% |
| 2017 Q1 | -4.89 Million SEK | -29.06% |
| 2017 FY | - SEK | -45.31% |
| 2017 Q4 | -8.68 Million SEK | -139.58% |
| 2017 Q2 | -4.89 Million SEK | 0.0% |
| 2016 Q4 | -3.79 Million SEK | 0.0% |
| 2016 FY | - SEK | -28.63% |
| 2015 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Active Biotech AB (publ) | -43.88 Million SEK | -24.88% |
| Amniotics AB (publ) | -27.14 Million SEK | -101.916% |
| BioArctic AB (publ) | 275.38 Million SEK | 119.901% |
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 85.099% |
| Camurus AB (publ) | 562.54 Million SEK | 109.743% |
| Cantargia AB (publ) | -284.31 Million SEK | 80.723% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | -179.922% |
| CombiGene AB (publ) | -35.33 Million SEK | -55.099% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | 61.089% |
| Genovis AB (publ.) | 64.57 Million SEK | 184.876% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | 52.304% |
| Mendus AB (publ) | -97.84 Million SEK | 43.987% |
| Isofol Medical AB (publ) | -37.02 Million SEK | -48.028% |
| Intervacc AB (publ) | -68.98 Million SEK | 20.548% |
| Kancera AB (publ) | -61.88 Million SEK | 11.445% |
| Karolinska Development AB (publ) | -26.78 Million SEK | -104.63% |
| LIDDS AB (publ) | -39.67 Million SEK | -38.155% |
| Lipum AB (publ) | -37.11 Million SEK | -47.649% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | -352.792% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | 274.519% |
| NextCell Pharma AB | -40.98 Million SEK | -33.722% |
| OncoZenge AB (publ) | 7.26 Million SEK | 854.28% |
| Saniona AB (publ) | -69.69 Million SEK | 21.363% |
| Simris Alg AB (publ) | -22.36 Million SEK | -145.074% |
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | 82.736% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | 80.568% |
| Xintela AB (publ) | -53.47 Million SEK | -2.497% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | 67.726% |
| Ziccum AB (publ) | -20.34 Million SEK | -169.423% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | -285.496% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | -220.793% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | 2740400.0% |
| Alligator Bioscience AB (publ) | -237.61 Million SEK | 76.935% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | -2534.904% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | -308.056% |
| Corline Biomedical AB | -1.69 Million SEK | -3141.041% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | 68.379% |
| Aptahem AB (publ) | -10 Million SEK | -447.555% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | 574.552% |
| Fluicell AB (publ) | -25.91 Million SEK | -111.492% |
| Biovica International AB (publ) | -119.5 Million SEK | 54.14% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | -29.798% |
| AcouSort AB (publ) | -16.7 Million SEK | -228.121% |
| Abliva AB (publ) | -93.6 Million SEK | 41.452% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | 82.825% |
| 2cureX AB (publ) | -35.13 Million SEK | -55.982% |
| I-Tech AB | 30.34 Million SEK | 280.61% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 92.33% |
| Cyxone AB (publ) | -20.41 Million SEK | -168.473% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | 46.506% |
| Biosergen AB | 228 Thousand SEK | 24137.719% |
| Nanologica AB (publ) | -62.11 Million SEK | 11.773% |
| SynAct Pharma AB | -222.7 Million SEK | 75.39% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | -24.954% |
| BioInvent International AB (publ) | -312.7 Million SEK | 82.474% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | 17812.895% |
| Alzinova AB (publ) | 41.99 Thousand SEK | 130593.583% |
| Oncopeptides AB (publ) | -231.62 Million SEK | 76.338% |
| Pila Pharma AB (publ) | -8.81 Million SEK | -521.914% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | 49.515% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | -377.862% |